Literature DB >> 2935831

[Evolution of Acinetobacter calcoaceticus in the hospital milieu, from 1971 to 1984].

M L Joly-Guillou, E Bergogne-Berezin.   

Abstract

During the last 10 years the authors have evaluated the increasing part played by Acinetobacter calcoaceticus in nosocomial infections and the increasing resistance of this species to antibiotics. The study involved 850 clinical strains isolated from 1971 to 1984, and 24 antibiotics were tested. A progressive increase in resistance to beta-lactam antibiotics, aminoglycosides and tetracycline was observed, and to date up to 80-90% of the strains are resistant to all but major drugs such as imipenem, ceftazidime, tobramycin and amikacin. A significant difference in susceptibility to the major antibiotics was noticed between Acinetobacter clinical strains isolated before and after 1980. A correlation study between the development of resistant strains and the hospital consumption of antibiotics showed that this was a factor to be taken into account. After the new Bichat Hospital was opened, in 1980, the rate at which var. anitratum strains were isolated rose from 77.5% to 94.5%. The opening of new departments (intensive care units) with a higher risk of infection and a totally different environment probably constitutes the most important factor in this evolution.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935831

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

Review 1.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 2.  Ochrobactrum anthropi bacteremia: report of four cases and short review.

Authors:  W V Kern; M Oethinger; A Kaufhold; E Rozdzinski; R Marre
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

3.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.